Altimmune (ALT) Total Current Liabilities (2010 - 2026)

Altimmune (ALT) has reported Total Current Liabilities for 17 consecutive years, with $11.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 15.56% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $11.3 million (up 15.56% YoY), while the FY2025 annual figure was $15.0 million, up 43.27% from the prior year.
• Total Current Liabilities eased to $11.3 million in Q1 2026 per ALT's latest filing, from $15.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $19.1 million in Q1 2022 and bottomed at $8.6 million in Q3 2024.
• Historically, Total Current Liabilities has averaged $12.9 million across 5 years, with a median of $12.1 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 94.67% — and 2025, when it tumbled 39.16%.
• Altimmune's Total Current Liabilities stood at $17.1 million in 2022, then fell by 28.8% to $12.1 million in 2023, then fell by 13.79% to $10.5 million in 2024, then jumped by 43.27% to $15.0 million in 2025, then dropped by 24.5% to $11.3 million in 2026.
• Business Quant data shows ALT's Total Current Liabilities at $11.3 million in Q1 2026, $15.0 million in Q4 2025, and $12.6 million in Q3 2025.